Literature DB >> 7901927

PCNA/cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer. An immunohistochemical, retrospective study.

G Botti1, G Chiappetta, G D'Aiuto, E de Angelis, A De Matteis, M Montella, A Picone, F Cascione.   

Abstract

AIMS AND
BACKGROUND: The aim of the present study was to determine, retrospectively, whether the immunohistochemical expression of two biologic markers of aggressively, P-glycoprotein (P-gp) and PCNA/cyclin (PCNA), could be related to response to chemotherapy and prognosis in locally advanced breast cancer.
METHODS: PC 10 Mab was used to determine the proliferation index (PCNA) and C-219 Mab to determine P-gp in 25 locally advanced breast carcinomas subjected to preoperative chemotherapy with MDR-related drugs.
RESULTS: P-gp and PCNA were expressed in 76% and 100% of the tumors, respectively. No case of high P-gp expression was associated with good chemosensitivity, and all P-gp-negative cases showed the best chemotherapeutic response. P-gp and PCNA were both highly expressed in patients who developed local-regional or distant metastases. No recurrence was associated with a negative or low P-gp score.
CONCLUSIONS: Statistical analysis showed that high P-gp expression was related to a poor response to chemotherapy and a short disease-free survival. A high PCNA score was not found to be significant for predicting chemosensitivity or survival.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901927     DOI: 10.1177/030089169307900312

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  2 in total

1.  P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer.

Authors:  L Seymour; W R Bezwoda; R D Dansey
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

2.  MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.

Authors:  F Leonessa; D Green; T Licht; A Wright; K Wingate-Legette; J Lippman; M M Gottesman; R Clarke
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.